Cisplatin

Pharmacogenetics of Resistance to Cisplatin and Other Anticancer Drugs and the Role of Sphingolipid Metabolism

Dictyostelium discoideum has proven to be a useful lead genetic system for identifying novel genes and pathways responsible for the regulation of sensitivity to the widely used anticancer drug cisplatin. Resistance to cisplatin

Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin

Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel

Gene Therapy Approaches to Sensitization of Human Prostate Carcinoma to Cisplatin by Adenoviral Expression of p53 and by Antisense Jun Kinase Oligonuc

One of the challenges of medical research today is to find ways of bringing our genetic knowledge of cancer to clinical application and to develop improved therapies by exploiting gene-based strategies. By offering increased specificity